Congresses & Events
Safety Profile - Kesimpta
Efficacy - Kesimpta
Safety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1,4 .Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plusDosing
Dosing¹
Posology & Method of AdministrationThe recommended dose is 200 mg taken orally twice daily.
Healthcare professionals should advise patients with PNH about the...
Twitter Linkedin Facebook Pinterest Google plusReimbursement
Unmet Need
